Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

BACKGROUND: ROS1 gene fusion represents a specific subtype of non‐small cell lung cancer (NSCLC). Crizotinib is recommended for ROS1‐positive NSCLC due to its favorable outcome in published clinical trials. However, due to the low incidence of ROS1‐positive NSCLC, there is limited information on rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Zhang, Quan, Liang, Li, Li, Junling, Liu, Zhefeng, Li, Weihua, Yang, Lu, Yang, Guangjian, Xu, Fei, Ying, Jianming, Zhang, Shucai, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221311/
https://www.ncbi.nlm.nih.gov/pubmed/32168429
http://dx.doi.org/10.1002/cam4.2984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221311/
https://www.ncbi.nlm.nih.gov/pubmed/32168429
http://dx.doi.org/10.1002/cam4.2984

Ejemplares similares